Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Therapeutic proteins are proteins that are engineered in the laboratory for pharmaceutical use, including non-covalent binders, therapeutic proteins such as enzymes and albumin are having properties such as breaking of covalent bongs and therefore has wide application of treatment .Therapeutic proteins are highly effective in vivo and in-vitro treatment of diseases. Oral vaccines are biologically prepared products, which provide active acquired immunity to diseases such as cholera, polio, rotavirus, smallpox, yellow fever, and others. An oral vaccine comprise an agent resembling to the disease causing microorganism. The vaccines are generally developed from live attenuated or killed forms of the disease causing microorganism, its toxins, or its surface proteins.

Figure 1. Global Therapeutic Proteins and Oral Vaccines Market Value (US$ Mn), 2016-2027

Therapeutic Proteins and Oral Vaccines  | Coherent Market Insights

The global therapeutic proteins and oral vaccines market size is estimated to be valued at US$ 201,042.7 million in 2020 and is expected to exhibit a CAGR of 6.7% over the forecast period (2020-2027).

The increasing investments by key players for the development of promising therapies for treatment of different disease conditions is expected to drive the market growth over the forecast period. For instance, in March 2020, research scientists at Migal Galilee Research Institute Ltd, the research and development center of MigVax Ltd, announced to develop a oral vaccine for a deadly coronavirus virus affecting poultry could be adapted for human use against the novel coronavirus known as 2019-nCoV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Moreover, increasing prevalence of oncology disease is expected to drive growth of the global therapeutic proteins and oral vaccines market. For instance, according to the World Health Organization report published in September 2018, cancer is the second leading cause of death globally, with around 70% of deaths occurring in low and middle income countries.

request-sample

Therapeutic Proteins and Oral Vaccines Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 201,042.7 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.7% 2027 Value Projection: US$ 316,684.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class:
    • Therapeutic Proteins: Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, Others.
    • Oral Vaccines: Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, Others.
  • By Application: Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
  • By Region: North America, Latin America, Europe, Asia Pacific, Middle East, Africa
Companies covered:

Abbott Laboratories, Amgen, Inc., Biogen, Inc, Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc. , TransAlgae, MigVax Ltd, and Lumen Bioscience, Inc

Growth Drivers:
  • Increasing prevalence of chronic diseases
  • Rising number of clinical trials by major companies
  • Key players focusing on increasing robust pipeline of biologics
  • Key players focusing on strategies such as collaborations
Restraints & Challenges:
  • Stringent regulatory scenario and
  • lower availability and affordability of therapeutic proteins in lower income countries

Global Therapeutic Proteins and Oral Vaccines Market- Impact of Coronavirus (Covid-19) Pandemic

The increasing prevalence of COVID-19 has caused production factories to shutdown in almost all sectors, and also affected the supply of raw materials and Active Pharmaceutical Ingredients (API) of the manufacturing companies across the globe. Moreover, various guidelines have been implemented by regulatory authorities for manufacturing of active pharmaceutical ingredients and pharmaceutical products to avoid the spread of COVID-19 and also to reduce the contamination of active pharmaceutical ingredients during the manufacturing process of pharmaceuticals products such as vaccines, tablets, and others.

According to the U.S. Food Drug and Administration’s report of June 2020, owing to the COVID-19 public health emergency, drug manufacturers are required to abide by the following current good manufacturing practice (CGMP) regulations and recommendations regarding restriction of sick employees from production areas. 1) Any employee or worker in a production unit should be medically evaluated for infectious diseases such as COVID-19. 2) If any of individual is exhibiting COVID-19 symptoms, they shall be restricted from entering the production house premises of the company to prevent contamination of drugs and active pharmaceutical ingredients (API).

Thus, the COVID-19 pandemic has negatively affected the Global therapeutic protein and oral vaccine market.

Figure 2. Global Therapeutic Proteins and Oral Vaccines Market Share (%) by Region, 2020

Therapeutic Proteins and Oral Vaccines  | Coherent Market Insights

In North America, increasing prevalence of cardiovascular disorders (CVDs) such as coronary heart failure and others is expected to drive the demand of therapeutic proteins for the treatment of cardiovascular diseases, which in turn is expected to boost growth of the global therapeutic proteins and oral vaccines market over the forecast period. For instance, according to the American Heart Association’s Heart Disease and Stroke Statistics 2018, around 92.1 million adults in the U.S. suffered from some form of CVD or the after-effects of stroke.

Moreover, in Europe, increasing number of conferences and symposiums conducted in Europe, which are focused on spreading knowledge about recent advancements in biopharmaceutical field is expected to create a lucrative environment for the market growth. For instance, in September 2018, 6th European Biopharma Congress was held at Amsterdam, Netherlands. The subject of this conference was novel strategies and advancements in biopharmaceutics. Researchers and scientists participating in this seminar discussed on cell therapy, biotechnology, therapeutic biological products, gene therapy, biosimilars, drug discovery, and clinical trials.

Furthermore, Middle-to-lower income countries such as India, Indonesia, Bangladesh, Mexico, Brazil, and certain European countries do not have proper availability of biologics due to high cost and lack of reimbursement for biologics. Therefore, lower availability and affordability of biologics in middle and lower income countries are expected to hamper the biologics market growth over the forecast period.  For instance, according to article 'Affordability Issues of Biotech Drugs in Low- and Middle-Income Countries (LMICs)' published in Drug Designing and Intellectual Properties International Journal 2019, in India alone, as many as 63 million people are forced into poverty every year, owing to very high health expenses, the majority of which are out-of-pocket payments for medicines. These factors are expected to restraint the global therapeutic proteins and oral vaccines market.

Key Players

Major players operating in global therapeutic proteins and oral vaccines market include Abbott Laboratories, Amgen, Inc., Biogen, Inc, Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd, and Lumen Bioscience, Inc

Oral administration of vaccines is the most convenient way of vaccination, owing to the factors such as oral vaccines are non-invasive, safe, and suitable for all age groups, especially children. Oral vaccines are mostly preferred for mass vaccination and are mostly liquid filled in sachet or blister. Oral vaccines are commonly available for diseases such as typhoid, cholera, adenovirus, rotavirus, and others.

Therapeutic proteins can be used to replace a protein that is abnormal or deficient in a particular disease. They can also augment the body’s supply of a beneficial protein to help reduce the impact of disease or chemotherapy. Genetically engineered proteins can closely resemble the natural proteins they replace, or they can be enhanced by adding sugars or other molecules that extend the protein’s duration of therapeutic activity in patients.

Market Dynamics

Key companies focusing on product approvals of oral vaccines and therapeutic proteins, is expected to drive the global therapeutic proteins and oral vaccines market. For instance, in July 2018, Emergent BioSolutions Inc. announced that it received marketing authorization from European Medicine Agency for its oral typhoid vaccine Vivotif (Typhoid Vaccine Live Oral Ty21a) in five European countries such as France, Portugal, Poland, Czech Republic, and Slovakia. Moreover, in May 2018,  Amgen Inc. received the U.S. Food and Drug Administration approval for Aimovig (erenumab-aooe), indicated for preventive treatment of migraine in adults.

Key features of the study:

  • This report provides in-depth analysis of the global therapeutic proteins and oral vaccines market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020 – 2027)
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
  • It profiles leading players in the global therapeutic proteins and oral vaccines based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
  • The global therapeutic proteins and oral vaccines market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
  • Stakeholders would greatly benefit in decision-making through various strategy matrices used in analyzing the global therapeutic proteins and oral vaccines market

Detailed Segmentation:

  • Global Therapeutic Proteins and Oral Vaccine Market, By Drug Class :
    • Therapeutic Proteins
      • Growth Factors
      • Fusion Proteins
      • Monoclonal Antibodies
      • Hormones
      • Coagulation Factors
      • Others
    • Oral Vaccines
      • Live Attenuated Vaccine
      • Inactivated Vaccine
      • Recombinant Vaccine
      • Others
  • Global Therapeutic Proteins and Oral Vaccine Market, By Application :
    • Oncology
    • Hematology
    • Immunology
    • Endocrinology
    • Infectious Disease
    • Cardiovascular Disease
    • Others
  • Global Therapeutic Proteins and Oral Vaccine Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Therapeutic Proteins and Oral Vaccine Market, By Region:
    • North America
      • By Drug Class:
        • Therapeutic Proteins
          • Growth Factors
          • Fusion Proteins
          • Monoclonal Antibodies
          • Hormones
          • Coagulation Factors
          • Others
        • Oral Vaccines
          • Live Attenuated Vaccine
          • Inactivated Vaccine
          • Recombinant Vaccine
          • Others
      • By Application :
        • Oncology
        • Hematology
        • Immunology
        • Endocrinology
        • Infectious Disease
        • Cardiovascular Disease
        • Others
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Therapeutic Proteins
          • Growth Factors
          • Fusion Proteins
          • Monoclonal Antibodies
          • Hormones
          • Coagulation Factors
          • Others
        • Oral Vaccines
          • Live Attenuated Vaccine
          • Inactivated Vaccine
          • Recombinant Vaccine
          • Others
      • By Application :
        • Oncology
        • Hematology
        • Immunology
        • Endocrinology
        • Infectious Disease
        • Cardiovascular Disease
        • Others
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Therapeutic Proteins
          • Growth Factors
          • Fusion Proteins
          • Monoclonal Antibodies
          • Hormones
          • Coagulation Factors
          • Others
        • Oral Vaccines
          • Live Attenuated Vaccine
          • Inactivated Vaccine
          • Recombinant Vaccine
          • Others
      • By Application :
        • Oncology
        • Hematology
        • Immunology
        • Endocrinology
        • Infectious Disease
        • Cardiovascular Disease
        • Others
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Therapeutic Proteins
          • Growth Factors
          • Fusion Proteins
          • Monoclonal Antibodies
          • Hormones
          • Coagulation Factors
          • Others
        • Oral Vaccines
          • Live Attenuated Vaccine
          • Inactivated Vaccine
          • Recombinant Vaccine
          • Others
      • By Application :
        • Oncology
        • Hematology
        • Immunology
        • Endocrinology
        • Infectious Disease
        • Cardiovascular Disease
        • Others
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Therapeutic Proteins
          • Growth Factors
          • Fusion Proteins
          • Monoclonal Antibodies
          • Hormones
          • Coagulation Factors
          • Others
        • Oral Vaccines
          • Live Attenuated Vaccine
          • Inactivated Vaccine
          • Recombinant Vaccine
          • Others
      • By Application :
        • Oncology
        • Hematology
        • Immunology
        • Endocrinology
        • Infectious Disease
        • Cardiovascular Disease
        • Others
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Therapeutic Proteins
          • Growth Factors
          • Fusion Proteins
          • Monoclonal Antibodies
          • Hormones
          • Coagulation Factors
          • Others
        • Oral Vaccines
          • Live Attenuated Vaccine
          • Inactivated Vaccine
          • Recombinant Vaccine
          • Others
      • By Application :
        • Oncology
        • Hematology
        • Immunology
        • Endocrinology
        • Infectious Disease
        • Cardiovascular Disease
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Abbott Laboratories.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Amgen, Inc.
    • Biogen, Inc.
    • Eily, Lilly, and Company
    •  F. Hoffmann-La Roche
    •  Johnson and Johnson
    •  Merck & Co.
    •  Novo Nordisk
    • Pfizer, Inc.
    • Sanofi S.A.
    • Serum Institute of India Pvt. Ltd.
    • Emergent Biosolutions Inc.
    • TransAlgae
    • MigVax Ltd
    • Lumen Bioscience, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Drivers
    • Restraints
    • Opportunities
    • Impact Analysis
    • Epidemiology 
    • Product Approvals
    • Product Launches
    • Mergers and Acquisitions
    • Pipeline Analysis
    • Regulatory Scenario
    • Reimbursement Scenario
    • Pest Analysis
    • Pricing Analysis & Major Brand Analysis
    • Treatment Algorithm
    • Competitive Intelligence
    • Manufacturing Technologies
    • Biosimilar Overview
  4. Global Therapeutic Proteins and Oral Vaccines Market - Impact of Coronavirus (Covid-19) Pandemic
    • Post COVID-19 Impact on Manufacturing
    • Impact on Research and Development
  5. Global Therapeutic Proteins and Oral Vaccines Market, By Drug Class, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
        • Introduction
        • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
        • Segment Trends
          • Therapeutic Proteins
            • Growth Factors
              • Introduction
              • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
            • Fusion Proteins
              • Introduction
              • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
            • Monoclonal Antibodies
              • Introduction
              • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
            • Hormones
              • Introduction
              • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
            • Coagulation Factors
              • Introduction
              • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
            • Others
              • Introduction
              • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
          • Oral Vaccines
            • Live Attenuated Vaccine
              • Introduction
              • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
            • Inactivated Vaccine
              • Introduction
              • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
            • Recombinant Vaccine
              • Introduction
              • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
            • Others
              • Introduction
              • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
  6. Global Therapeutic Proteins and Oral Vaccines Market, By Application, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017– 2027
      • Segment Trends
        • Oncology
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Hematology
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Immunology
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Endocrinology
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Infectious Disease
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Cardiovascular Disease
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
  7. Global Therapeutic Proteins and Oral Vaccines Market, By Distribution Channel, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017– 2027
      • Segment Trends
        • Polymerase Chain Reaction ( PVR)
        • Hospital Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Retail Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Online Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
  8. Global Therapeutic Proteins and Oral Vaccines Market, By Region, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Drug Class, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2020–2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Drug Class, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2020–2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Drug Class, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2020–2027 (US$ Mn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Drug Class, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2020–2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Drug Class, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2020–2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Drug Class, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2020–2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • Abbott Laboratories
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amgen, Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Biogen, Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eily, Lilly, and Company
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      •  F. Hoffmann-La Roche
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      •  Johnson and Johnson
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      •  Merck & Co.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      •  Novo Nordisk
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi S.A.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Serum Institute of India Pvt. Ltd.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Emergent Biosolutions Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • TransAlgae
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • MigVax Ltd
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lumen Bioscience, Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies

*Browse 40 market data tables and 33 figures on "Global Therapeutic Proteins and Oral Vaccines Market– Regional forecast to 2027”.

FAQgrowicon

Frequently Asked Questions

The global therapeutic proteins and oral vaccines market size is estimated to be valued at US$ 201,042.7 million in 2020 and is expected to exhibit a CAGR of 6.7% between 2020 and 2027.
Increasing prevalence of chronic diseases such as cancer and cardiovascular diseases and key company focusing on clinical trials of therapeutic proteins and oral vaccines for the treatment chronic diseases
Therapeutic proteins segment is estimated to hold major market share in 2020, owing to rising approval of monoclonal antibodies by regulatory agencies, which is favouring launch of innovative therapeutics
Oncology market segment is estimated to hold major market share in 2020, owing to owing to increasing prevalence of cancer such as lung cancer and breast cancer globally.
Hospital pharmacies segment is estimated to hold major market share in 2020, owing to rising prevalence of various diseases such as non-small cell lung cancers, leukemia, osteoporosis, and diabetes mellitus, which is expected to drive the demand for therapeutic protein treatment and oral vaccines, which in turn is expected to exhibit growth during the forecast period
North America market is estimated to generate highest revenue share in 2020 in the during the forecast period.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner